VITROLIFE AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 172.2 SEK | -0.06% |
|
-1.15% | -11.56% |
| May. 22 | Sweden's Vitrolife Wraps Up Purchase of Software Group eFertility | MT |
| May. 22 | Vitrolife AB (OM:VITR) acquired Stb Zorg B.V. | CI |
| Sales 2024 * | 3.65B 345M | Sales 2025 * | 3.97B 376M | Capitalization | 23.31B 2.21B |
|---|---|---|---|---|---|
| Net income 2024 * | 565M 53.48M | Net income 2025 * | 675M 63.89M | EV / Sales 2024 * | 6.55 x |
| Net Debt 2024 * | 587M 55.53M | Net cash position 2025 * | 128M 12.09M | EV / Sales 2025 * | 5.84 x |
| P/E ratio 2024 * |
41.3
x | P/E ratio 2025 * |
34.6
x | Employees | 1,132 |
| Yield 2024 * |
0.69% | Yield 2025 * |
0.8% | Free-Float | 55.35% |
More Fundamentals
* Assessed data
More news
Latest transcript on Vitrolife AB
More press releases
More news
| 1 day | -0.06% | ||
| 1 week | -1.15% | ||
| Current month | -6.77% | ||
| 1 month | -8.16% | ||
| 3 months | -13.12% | ||
| 6 months | -11.37% | ||
| Current year | -11.56% |
1 week
171.20
179.60
1 month
170.50189.20
Current year
156.00205.40
1 year
123.90216.60
3 years
123.90585.00
5 years
112.30585.00
10 years
20.75585.00
| Managers | Title | Age | Since |
|---|---|---|---|
Bronwyn Brophy
CEO | Chief Executive Officer | - | 23-07-31 |
Patrik Tolf
DFI | Director of Finance/CFO | 54 | 21-12-31 |
| Chairman | 68 | 15-05-06 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 53 | 19-05-01 | |
| Chairman | 68 | 15-05-06 | |
| Director/Board Member | 64 | 18-04-26 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.37% | 262 M€ | +6.76% | ||
| 0.02% | 775 M€ | -.--% | - | |
| 0.01% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-26 | 172.2 | -0.06% | 36,313 |
| 24-06-25 | 172.3 | -3.74% | 33,881 |
| 24-06-24 | 179 | +2.34% | 41,512 |
| 24-06-20 | 174.9 | +0.40% | 122,515 |
| 24-06-19 | 174.2 | +0.87% | 90,585 |
Delayed Quote Nasdaq Stockholm, June 26, 2024 at 12:00 pm EDT
More quotes
Vitrolife AB is a Sweden-based company engaged in assisted reproduction services. The Companyâs product portfolio comprises G-RINSE, which is a solution for rinsing of contact materials, EmbryoGlue, which is a human albumin recombinant, ASP, which is a solution for oocyte retrieval and rinsing, and Semen VTS, which is a viscosity treatment system, among others. It also provides a range of procedural solutions for sperm preparation, vitrification, embryo transfer and oocyte retrieval, such as temperature control, condition control, gamete-safe labware and embryo support. The Company is active in Australia, China, France, Italy, Japan, the United States and the United Kingdom, among others, and conducts its business through a number of subsidiaries, such as Vitrolife Ltd., Vitrolife Pty Ltd., and A.T.S. Srl.
Calendar
2024-07-17
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
172.2
SEK
Average target price
231.7
SEK
Spread / Average Target
+34.53%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -11.56% | 2.21B | |
| -8.90% | 11.57B | |
| -12.79% | 7.37B | |
| +26.65% | 5.44B | |
| -17.87% | 3.74B | |
| +7.41% | 2.58B | |
| -65.15% | 2.33B | |
| +28.63% | 2.23B | |
| -14.32% | 1.67B | |
| -9.41% | 1.4B |
- Stock Market
- Equities
- VITR Stock
